Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.54−0.08 (-13.14%)
Close on Nov 17, 2026Market cap $211.76MP/E 2.5Yield –
Standard BioTools revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Standard BioTools's revenue for the twelve months ending Jun 30, 2026 was $84.60M, down 4.8% year over year. For fiscal 2025 it was $85.33M, down 6.2% from the year before. Over ten years it grew -2.9% a year on average. The highest annual figure on record is $138.14M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.33M | -6.2% |
| FY2024 | Dec 31, 2024 | $91.01M | -14.4% |
| FY2023 | Dec 31, 2023 | $106.34M | +8.6% |
| FY2022 | Dec 31, 2022 | $97.95M | -25.0% |
| FY2021 | Dec 31, 2021 | $130.58M | -5.5% |
| FY2020 | Dec 31, 2020 | $138.14M | +17.8% |
| FY2019 | Dec 31, 2019 | $117.24M | +3.8% |
| FY2018 | Dec 31, 2018 | $112.96M | +10.8% |
| FY2017 | Dec 31, 2017 | $101.94M | -2.4% |
| FY2016 | Dec 31, 2016 | $104.45M | -8.9% |
| FY2015 | Dec 31, 2015 | $114.71M | -1.5% |
| FY2014 | Dec 31, 2014 | $116.46M | +63.6% |
| FY2013 | Dec 31, 2013 | $71.18M | +36.0% |
| FY2012 | Dec 31, 2012 | $52.33M | +22.1% |
| FY2011 | Dec 31, 2011 | $42.87M | +27.7% |
| FY2010 | Dec 31, 2010 | $33.56M | +32.1% |
| FY2009 | Dec 31, 2009 | $25.41M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $20.10M | -7.6% |
| Q1 FY2026 | Mar 31, 2026 | $21.15M | +4.6% |
| Q4 FY2025 | Dec 31, 2025 | $23.80M | -4.0% |
| Q3 FY2025 | Sep 30, 2025 | $19.55M | -11.5% |
| Q2 FY2025 | Jun 30, 2025 | $21.76M | -3.2% |
| Q1 FY2025 | Mar 31, 2025 | $20.22M | -55.6% |
| Q4 FY2024 | Dec 31, 2024 | $24.78M | -12.1% |
| Q3 FY2024 | Sep 30, 2024 | $22.09M | -12.9% |
| Q2 FY2024 | Jun 30, 2024 | $22.49M | -18.7% |
| Q1 FY2024 | Mar 31, 2024 | $45.54M | +81.3% |
| Q4 FY2023 | Dec 31, 2023 | $28.19M | +4.3% |
| Q3 FY2023 | Sep 30, 2023 | $25.37M | -1.1% |
| Q2 FY2023 | Jun 30, 2023 | $27.67M | +47.3% |
| Q1 FY2023 | Mar 31, 2023 | $25.12M | -5.2% |
| Q4 FY2022 | Dec 31, 2022 | $27.02M | -29.4% |
| Q3 FY2022 | Sep 30, 2022 | $25.65M | -10.0% |
| Q2 FY2022 | Jun 30, 2022 | $18.78M | -39.5% |
| Q1 FY2022 | Mar 31, 2022 | $26.50M | -19.2% |
| Q4 FY2021 | Dec 31, 2021 | $38.27M | -14.2% |
| Q3 FY2021 | Sep 30, 2021 | $28.50M | -28.5% |
| Q2 FY2021 | Jun 30, 2021 | $31.02M | +19.0% |
| Q1 FY2021 | Mar 31, 2021 | $32.79M | +18.7% |
| Q4 FY2020 | Dec 31, 2020 | $44.61M | +37.5% |
| Q3 FY2020 | Sep 30, 2020 | $39.86M | +50.4% |
| Q2 FY2020 | Jun 30, 2020 | $26.06M | -7.6% |
| Q1 FY2020 | Mar 31, 2020 | $27.62M | -8.3% |
| Q4 FY2019 | Dec 31, 2019 | $32.44M | +0.4% |
| Q3 FY2019 | Sep 30, 2019 | $26.50M | -8.5% |
| Q2 FY2019 | Jun 30, 2019 | $28.20M | +6.7% |
| Q1 FY2019 | Mar 31, 2019 | $30.11M | +19.3% |
| Q4 FY2018 | Dec 31, 2018 | $32.33M | +16.5% |
| Q3 FY2018 | Sep 30, 2018 | $28.96M | +17.0% |
| Q2 FY2018 | Jun 30, 2018 | $26.43M | +10.5% |
| Q1 FY2018 | Mar 31, 2018 | $25.25M | -1.1% |
| Q4 FY2017 | Dec 31, 2017 | $27.75M | +10.6% |
| Q3 FY2017 | Sep 30, 2017 | $24.75M | +11.5% |
| Q2 FY2017 | Jun 30, 2017 | $23.91M | – |
| Q1 FY2017 | Mar 31, 2017 | $25.53M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.08M | – |
| Q3 FY2016 | Sep 30, 2016 | $22.19M | – |
See a number that looks wrong?